文献速递甲状腺疾病

Sapanisertib治疗晚期未分化甲状腺癌和放射性碘难治性分化型甲状腺癌的I/II期试验

A Phase I/II Trial of Sapanisertib in Advanced Anaplastic and Radioiodine Refractory Differentiated Thyroid Carcinoma.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

这项多中心I/II期试验评估了mTOR复合物1/2口服抑制剂sapanisertib在未分化甲状腺癌(ATC)和放射性碘难治性分化型甲状腺癌(RAIR DTC)中的疗效。46例患者入组(20例ATC,26例DTC),其中40例接受了II期推荐剂量5 mg每日一次。ATC队列因总体无效提前终止,18例中仅11%(2/18,95%CI:1.4-34.7%)在4个月时无疾病进展,未达到主要终点;RAIR DTC中1例确认部分缓解(4.5%,1/22),63.6%(14/22)疾病稳定。

要点

  • ATC患者4个月无进展比例为11%(2/18,95%CI:1.4-34.7%),未达到主要终点。
  • ATC队列因总体无效提前终止,18例入组而未达计划的23例。
  • RAIR DTC中确认部分缓解1例(4.5%,1/22),疾病稳定63.6%(14/22)。

核心结论

  • Sapanisertib单药治疗未达到本试验在ATC中的主要终点(4个月无进展比例),未显示有临床意义的活性;需要采用替代治疗策略的临床试验。

研究设计与样本

  • 多中心试验,先进行安全性导入I期,随后在ATC中开展非随机II期试验,并在RAIR DTC中设探索性队列。
  • 共入组46例患者(20例ATC,26例DTC),其中40例(18例ATC,22例DTC)接受了II期推荐剂量5 mg每日一次。
  • 主要终点为ATC患者4个月时无疾病进展的比例;安全性和生存结局为关键次要终点。

主要发现

  • ATC患者4个月无进展比例为11%(2/18,95%CI:1.4-34.7%);最佳缓解为疾病稳定者占22.2%(4/18)。
  • RAIR DTC中确认部分缓解1例(4.5%,1/22),疾病稳定63.6%(14/22)。
  • ATC和DTC的中位无进展生存期分别为1.6个月(95%CI:0.9-2.8)和7.8个月(95%CI:2.0-未达到)。
  • 接受II期剂量患者中30%发生3级治疗相关不良事件,最常见为厌食、恶心、腹泻、乏力、皮疹和高血糖。
  • PI3K/AKT/mTOR通路基因组改变与缓解或无进展生存期无关。

局限性

  • ATC队列因总体无效提前终止,入组18例而非计划的23例。
  • 原文结论指出需要采用替代治疗策略的临床试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There are limited therapeutic options for patients with recurrent/metastatic anaplastic thyroid carcinoma (ATC) and radioiodine refractory (RAIR) differentiated thyroid carcinoma (DTC) refractory to multikinase inhibitors. This multicenter trial evaluated sapanisertib, a next-generation oral kinase inhibitor of mTOR complexes 1/2, in ATC and RAIR DTC. METHODS: A safety run-in phase I was followed by nonrandomized phase II trial in ATC, with an exploratory cohort in RAIR DTC. The primary endpoint was the proportion of patients with ATC who were without disease progression at 4 months. Safety and survival outcomes were key secondary endpoints. RESULTS: Forty-six patients (20 ATC, 26 DTC) were enrolled including 40 (18 ATC, 22 DTC) who received recommended phase II dose of 5 mg daily. Eleven percent [2/18, 95% confidence interval (CI): 1.4-34.7%] of patients with ATC were progression-free at 4 months; 22.2% (4/18) had stable disease as best response. Enrollment in the ATC cohort stopped early with 18 patients out of the proposed 23 due to overall futility. One confirmed partial response (4.5%, 1/22) occurred in RAIR DTC, with stable disease in 63.6% (14/22) patients. Median progression-free survival was 1.6 (95% CI: 0.9-2.8) months and 7.8 (2.0-not reached) months in ATC and DTC, respectively. Grade 3 treatment-related adverse events occurred in 30% of patients who received the phase II dose, with the most common being anorexia, nausea, diarrhea, fatigue, skin rash, and hyperglycemia. Genomic alterations in the PI3K/AKT/mTOR pathway were not associated with response or progression-free survival. CONCLUSION: Sapanisertib monotherapy did not meet the primary endpoint of this trial (proportion progression-free at 4 months) in ATC and did not show clinically meaningful activity. Clinical trials with alternative therapeutic strategies are needed.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Sehgal K, Serritella A, Liu M, et al. A Phase I/II Trial of Sapanisertib in Advanced Anaplastic and Radioiodine Refractory Differentiated Thyroid Carcinoma. J Clin Endocrinol Metab. 2025. PMID: 38943664. doi:10.1210/clinem/dgae443

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。